This file contains STRIKE and UNDERSCORE. If you cannot see either STRIKE or UNDERSCORE attributes or would like to change how these attributes are displayed, please use the following form to make the desired changes.

House Journal: Page 1131: Wednesday, April 9, 1997

Blodgett of Cerro Gordo asked and received unanimous consent to
withdraw amendments H-1604 and H-1633, filed by him and Hansen
of Pottawattamie on April 8, 1997, and amendment H-1644 filed by
Blodgett of Cerro Gordo from the floor.
Hansen of Pottawattamie offered the following amendment H-1635
filed by Hansen, et al., and moved its adoption:

H-1635

 1     Amend House File 715 as follows:
 2     1.  Page 15, by striking lines 21 and 22 and
 3   inserting the following:
 4     "1.  a.  The department shall continue prospective
 5   drug utilization review and may establish drug
 6   surveillance prior authorization under the medical
 7   assistance program.
 8     b.  The department shall develop and implement an
 9   individual patient tracking system to assess the
10   effectiveness of the drug prior authorization program.
11   The system shall include patient specific elements
12   including, at a minimum, the drug prescribed or
13   requested, the alternative drug dispensed, the
14   quantity requested, the quantity dispensed, and the
15   drugs dispensed during required trials.
16     c.  The department shall conduct a prior
17   authorization cost-effectiveness study, at no cost to
18   the state, and shall not use any entity or individual
19   currently or previously utilized by the department to
20   perform the study.
21     d.  The prospective drug utilization review and
22   prior authorization cost-effectiveness studies shall
23   include, but are not limited to, all of the following:
24     (1)  The net cost of the substitution of brand name
25   drugs for which alternatives are required, including
26   the drug rebates, if applicable, under the Iowa prior
27   authorization regimen.
28     (2)  The costs attributable to the ambulatory
29   treatment of iatrogenic, unexpected conditions which
30   result when the prescribed drug is not authorized and
31   a substitution is made under the Iowa prior
32   authorization regimen, when it is possible to
33   determine that the conditions resulted from the
34   substitution of the alternative medication for the
35   prescribed medication.
36     (3)  The costs attributable to institutionalization
37   and treatment for iatrogenic, unexpected conditions
38   which result when the prescribed drug is not
39   authorized and a substitution is made under the Iowa
40   prior authorization regimen when it is possible to
41   determine that the condition resulted from the
42   substitution of the alternative medication for the

Iowa General Assembly

Index: House Journal (77th General Assembly: Session 1)

© 1997 Cornell College and League of Women Voters of Iowa

Comments about this site or page? hjourn@legis.iowa.gov. Please remember that the person listed above does not vote on bills. Direct all comments concerning legislation to State Legislators.

Last update: Tue Apr 15 03:40:03 CDT 1997
URL: /DOCS/GA/77GA/Session.1/HJournal/01100/01131.html
jhf